Clinical Trials - March 12, 2020
Gedea Biotech reports results from clinical study
Gedea Biotech, has reported results from a clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). In this open-label, single-armed, multi-center study, 82% of the women were clinically cured after 7 days. The cure rate corresponds to existing antibiotic-based treatment. Gedea wishes to caution however, that whilst […]
Clinical Trials - December 19, 2019
Gedea Biotech reports last patient visit in vulvovaginal candidiasis clinical study
Gedea Biotech has announced that all patients have been recruited for the multi-center study evaluating the clinical performance of an antibiotic-free treatment for vaginal infections. This pilot study marks the start of a clinical development program of a treatment with dual effect, targeting both vaginal bacterial and fungal infections. The study will be followed by […]
Clinical Trials - November 4, 2019
All patients treated in Gedea Biotech’s study in women with bacterial vaginosis
Gedea Biotech reports that all 24 patients have been treated with its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis in a proof of concept clinical study. In this open-label, single-armed, multi-center study, promising results have been seen when it comes to clinical performance, tolerability, and safety, reports the company. Final […]
